by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y Process \ A \ B \...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A Process \ An...
Recent Comments